Sandbox:YK: Difference between revisions
Jump to navigation
Jump to search
m (Changes made per Mahshid's request) |
|||
(172 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
== | ==Actinomycosis== | ||
===Treatment=== | |||
{| class="wikitable" | |||
!Type | |||
!Treatment | |||
! | |||
! | |||
|- | |- | ||
|Central Nervous system | |||
| | actinomycosis | ||
| | |||
|- | |- | ||
| | |||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | |} | ||
| | ==Amoebic liver abscess diagnosis== | ||
|- | {{familytree/start}} | ||
{{familytree | | | | | | | | | | | | A01 | | | | A01='''Diagnosis of amoebic liver abscess'''}} | |||
| || || || || | {{familytree | | | | | | | | | | | | |!| | | | |}} | ||
|- | {{familytree | | | | | | | | | | | | B01 | | | | B01='''Signs and symptoms'''(a)<br> Fever, abdominal pain, point tenderness over the liver, hepatomegaly, weight loss<br> '''History''' <br> Travel to endemic areas, immigrant from endemic areas, having had dysentery within last years, gender (male/female:9/1 }} | ||
{{familytree | | | | | | | | | | | | |!| | | | |}} | |||
| || || | {{familytree | | | | | | | | | | | | C01 | | | | C01= Laboratory diagnosis(LD) and Radiologic Methods (RM) (US, CT or MRI)}} | ||
| | {{familytree | | | | | | | | | | | | |!| | | | |}} | ||
{{familytree | | | |,|-|-|-|-|-|-|-|-|+|-|-|-|-|-|-|-|.| |}} | |||
| || || | {{familytree | | | D01 | | | | | | | D02 | | | | | | |D03 | |D01=LD negative and RM negative:Floow|D02=LD negative and RM positive:aspiration, if possible(b)|D03=LD positive and RM positive: chemotherapy / surgical treatment}} | ||
|- | {{familytree | | | | | | | | | | | | |!| | | | | | | | | |}} | ||
{{familytree | | | | | | |,|-|-|-|-|-|^|-|-|-|-|-|.| |}} | |||
| || || | {{familytree | | | | | | E01 | | | | | | | | | | E02 |E01=Pyogenic abscesses <br> Neoplasia (hepatocellular carcinoma)<br>Cysticercosis<br>Cystic echinococcosis|E02=ALA}} | ||
| | {{familytree/end}} | ||
! | |||
| || || | ==Liver abscess== | ||
{{familytree/start}} | |||
{{familytree | | | | | | | | | | | | A01 | | | | A01='''Liver abscess'''}} | |||
{{familytree | | | | | | | | | | | | |!| | | | |}} | |||
{{familytree | | | | | | | | | | | | B01 | | | | B01='''Risk factors'''}} | |||
{{familytree | | | |,|-|-|-|-|-|v|-|-|^|-|-|v|-|-|-|-|-|.|}} | |||
{{familytree | | | C01 | | | | C02 | | | | C03 | | | | C04 |C01='''Hematogenous'''|C02='''Biliary'''|C03='''Underlying lesions or anamolies'''|C04='''Other causes'''}} | |||
{{familytree | | | |!| | | | | |!| | | | | |!| | | | | |!|}} | |||
{{familytree | | | D01 | | | | D02 | | | | D03 | | | | D04 | D01='''Portal vein'''<br>Intra-abdominal [[infection]]<br>Pyelophlebitis<br>[[Abdominal abscess]]<br>[[Amoebiasis]] <br> '''Arterial'''<br>[[ENT]]<br>[[Oral cavity]]|D02=[[Gall stones]]<br>Obstructed bile duct<br>Contiguous spread, [[ascending cholangitis]]<br>[[Bile duct]] [[ischemia]]|D03=Biliary cyst<br>[[Hydatid cyst]]<br>[[Cystadenoma]]<br>[[Necrosis]] of a [[primary tumor]]<br>[[Superinfection]] of a [[metastasis]]<br>[[Caroli disease]]<br>Biliary stricture<br>[[Sclerosing cholangitis]]<br>Ischemic cholangitis|D04=[[Radiofrequency ablation]] / [[Chemoembolization]] in the presence of infected [[bile]]<br>Pancreatoduodenectomy<br>[[Liver transplantation]]<br>Hepatic trauma ± arterial embolization}} | |||
{{familytree/end}} | |||
==Causes liver abscess== | |||
|} | {{familytree/start}} | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | A01 | | | | A01='''Pyogenic liver abscess'''}} | |||
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | |!| |}} | |||
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | B01 | | B01='''Causes'''}} | |||
{{familytree | | | | |,|-|-|-|-|-|-|-|-|-|-|v|-|-|-|-|-|-|-|-|-|+|-|-|-|-|-|-|-|-|-|v|-|-|-|-|-|-|-|-|-|.|}} | |||
{{familytree | | | | C01 | | | | | | | | | C02 | | | | | | | | C03 | | | | | | | | C04 | | | | | | | | C05 |C01='''Hepatobiliary'''|C02='''Portal'''|C03='''Arterial'''|C04='''Traumatic'''|C05='''Cryptogenic'''}} | |||
{{familytree | | | | |!| | | | | | | | | | |!| | | | | | | | | |!| | | | | | | | | | |!| | | |}} | |||
{{familytree | |,|-|-|^|-|-|.| | | | |,|-|-|^|-|-|.| | | | | | |!| | | | | | |,|-|-|-|^|-|-|-|.|}} | |||
{{familytree | D01 | | | | D02 | | | D03 | | | | D04 | | | | | D05 | | | | | D06 | | | | | | D07 |D01=Benign|D02=Malignant|D03=Benign|D04=Malignant|D05= • Endocarditis<br> • Vascular sepsis<br> • Dental infection<br> • ENT infection|D06=Benign|D07=Malignant}} | |||
{{familytree | |!| | | | | |!| | | | |!| | | | | |!| | | | | | | | | | | | | |!| | | | | | | |!|}} | |||
{{familytree | E01 | | | | E02 | | | E03 | | | | E04 | | | | | | | | | | | | E05 | | | | | | E06|E01= • Lithiasis<br> • Cholicystitis<br> • Biliary enteric anastomosis<br> • Percutaneous biliary procedures<br> • Endoscopic biliary procedures|E02= • Gall bladder<br> • Common bile duct<br> • Head of pancreas<br> • Ampulla|E03= • Appendicitis<br> • Diverticulitis<br> • Pelvic suppuration<br> • Anorectal suppuration<br> • Pancreatic abscess<br> • Postoperative sepsis<br> • Intestinal perforation<br> • Inflammatory bowel disease|E04= • Gastric cancer<br> • Colon cancer|E05= • Open or closed abdominal trauma|E06= • Percutaneous ethanol injection or radiofrequency<br> • Chemoembolization}} | |||
{{familytree/end}} | |||
==Treatment== | |||
{{Family tree/start}} | |||
{{Family tree | | | | | | A01 | | | |A01= '''Treatment'''}} | |||
{{Family tree | | | |,|-|-|^|-|-|.|}} | |||
{{Family tree | | | B01 | | | | B01|B01=Non-surgical treatment|B02=Open surgical drainage}} | |||
{{family tree | |,|-|^|-|.|}} | |||
{{family tree | C01 | | C02|C01=Conservative management with antibiotics alone|C02=Open surgical drainage}} | |||
{{Family tree/end}} | |||
==Drainage== | |||
{{Family tree/start}} | |||
{{Family tree | | | | | | | A01 | | | |A01= '''Drainage'''}} | |||
{{Family tree | | | |,|-|-|-|+|-|-|-|.|}} | |||
{{Family tree | | | B01 | | B02 | | B03|B01=Percutaneous drainage|B02=Open surgical drainage|B03=Endoscopic retrograde cholangiopancreatography (ERCP)}} | |||
{{family tree | |,|-|^|-|.|}} | |||
{{family tree | C01 | | C01 |C01=CT guided|C02=Ultrasound guided}} | |||
{{Family tree/end}} | |||
The mainstay of therapy for pyogenic liver abscesses is [[percutaneous]] drainage and antimicrobial therapy. Empiric therapy for pyogenic [[liver]] [[abscesses]] consists of either a second- or third-generation [[cephalosporin]] with [[metronidazole]] or [[piperacillin-tazobactam]]. [[Amoebiasis|Amebic liver abscesses]] are often treated medically with a short course of [[metronidazole]] or [[tinidazole]] followed by 20 days of [[iodoquinol]]. | |||
==Medical Therapy== | |||
*It is essential to differentiate between pyogenic and amebic liver abscesses for appropriate therapy. Differentiation can be established based on [[serology]], culture results, and response to therapy.<ref name="pmid15189463">{{cite journal| author=Lodhi S, Sarwari AR, Muzammil M, Salam A, Smego RA| title=Features distinguishing amoebic from pyogenic liver abscess: a review of 577 adult cases. | journal=Trop Med Int Health | year= 2004 | volume= 9 | issue= 6 | pages= 718-23 | pmid=15189463 | doi=10.1111/j.1365-3156.2004.01246.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15189463 }} </ref> | |||
*The mainstay of therapy for pyogenic hepatic abscesses is [[ultrasound]]/CT-guided percutaneous drainage with at least 2 weeks (may last up to 6 weeks) of intravenous [[antibiotics]].<ref name="pmid21435221">{{cite journal| author=Heneghan HM, Healy NA, Martin ST, Ryan RS, Nolan N, Traynor O et al.| title=Modern management of pyogenic hepatic abscess: a case series and review of the literature. | journal=BMC Res Notes | year= 2011 | volume= 4 | issue= | pages= 80 | pmid=21435221 | doi=10.1186/1756-0500-4-80 | pmc=PMC3073909 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21435221 }} </ref> | |||
*Empiric [[antibiotics]] should only be used initially, with [[diagnostic]] aspiration and culture performed as soon as possible. | |||
*Amebic liver abscesses can be treated successfully with antimicrobial agents and do not require drainage except in special conditions, such as:<ref name="pmid12660071">{{cite journal| author=Stanley SL| title=Amoebiasis. | journal=Lancet | year= 2003 | volume= 361 | issue= 9362 | pages= 1025-34 | pmid=12660071 | doi=10.1016/S0140-6736(03)12830-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12660071 }} </ref> | |||
:*Severe clinical illness | |||
:*Uncertain diagnosis | |||
:*No response to [[metronidazole]] therapy (after 4 days of treatment) | |||
| | :*Large left-lobe abscesses (risk of rupture into [[pericardium]]) | ||
| | :*Imminent rupture | ||
|- | |||
| | |||
| | |||
== | ===Antibiotic Regimens=== | ||
* '''Pyogenic Liver Abscess''' | |||
:* '''1. Empiric antimicrobial therapy'''<ref name="pmid15578367">{{cite journal| author=Rahimian J, Wilson T, Oram V, Holzman RS| title=Pyogenic liver abscess: recent trends in etiology and mortality. | journal=Clin Infect Dis | year= 2004 | volume= 39 | issue= 11 | pages= 1654-9 | pmid=15578367 | doi=10.1086/425616 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15578367 }} </ref><ref name="pmid15667489">{{cite journal| author=Lederman ER, Crum NF| title=Pyogenic liver abscess with a focus on Klebsiella pneumoniae as a primary pathogen: an emerging disease with unique clinical characteristics. | journal=Am J Gastroenterol | year= 2005 | volume= 100 | issue= 2 | pages= 322-31 | pmid=15667489 | doi=10.1111/j.1572-0241.2005.40310.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15667489 }} </ref><ref name="pmid26287275">{{cite journal| author=Lübbert C, Wiegand J, Karlas T| title=Therapy of Liver Abscesses. | journal=Viszeralmedizin | year= 2014 | volume= 30 | issue= 5 | pages= 334-41 | pmid=26287275 | doi=10.1159/000366579 | pmc=PMC4513824 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26287275 }} </ref><ref name="pmid15245694">{{cite journal| author=Kurland JE, Brann OS| title=Pyogenic and amebic liver abscesses. | journal=Curr Gastroenterol Rep | year= 2004 | volume= 6 | issue= 4 | pages= 273-9 | pmid=15245694 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15245694 }} </ref><ref name="pmid21435221">{{cite journal| author=Heneghan HM, Healy NA, Martin ST, Ryan RS, Nolan N, Traynor O et al.| title=Modern management of pyogenic hepatic abscess: a case series and review of the literature. | journal=BMC Res Notes | year= 2011 | volume= 4 | issue= | pages= 80 | pmid=21435221 | doi=10.1186/1756-0500-4-80 | pmc=PMC3073909 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21435221 }} </ref> | |||
|- | ::* Preferred regimen (1): ([[Ceftriaxone]] 1-2 g IV/IM q24h {{or}} [[Cefotaxime]] 1-2 g IV or IM q8h) {{and}} ([[Metronidazole]] 15 mg/kg IV single dose {{then}} 7.5 mg/kg PO/IV q6h) | ||
| | ::* Preferred regimen (2): [[Ciprofloxacin]] 400 mg IV q12h {{and}} ([[Metronidazole]] 15 mg/kg IV single dose {{then}} 7.5 mg/kg PO/IV q6h) | ||
| | ::* Preferred regimen (3): [[Piperacillin-Tazobactam]] 3.375 g IV q6h | ||
|- | ::* Note: The empiric therapy for pyogenic abscesses should be based on local resistance patterns, with particular attention to resistant Klebsiella spp.. Ampicillin is not recommended due to the high resistance found among Klebsiella spp.. There is no set duration for treatment, which may vary from 2 to 6 weeks. | ||
| | :* '''2. Pathogen-directed antimicrobial therapy''' | ||
| | ::* '''2.1 Klebsiella spp.'''<ref name="pmid15667489">{{cite journal| author=Lederman ER, Crum NF| title=Pyogenic liver abscess with a focus on Klebsiella pneumoniae as a primary pathogen: an emerging disease with unique clinical characteristics. | journal=Am J Gastroenterol | year= 2005 | volume= 100 | issue= 2 | pages= 322-31 | pmid=15667489 | doi=10.1111/j.1572-0241.2005.40310.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15667489 }} </ref> | ||
|- | :::* Preferred regimen: [[Gentamicin]] {{and}} ([[Piperacillin-Tazobactam]] 3.375 g IV q6h {{or}} [[Cefazolin]] 0.5-1 g IV q6-8h {{or}} [[Ceftriaxone]] 1-2 g IV/IM q24h {{or}} [[Cefotaxime]] 1-2 g IV or IM q8h) for 2–3 wk | ||
| | :::*Note: Acute therapy may be followed by 4 weeks of oral antibiotics (fluoroquinolone or second/third-generation cephalosporin). | ||
* '''Amebic Liver Abscess''' | |||
|- | :* Preferred regimen (1): [[Metronidazole]] 2-4 g PO qd for 2 days {{then}} [[Iodoquinol]] 650 mg PO tid for 20 days | ||
| | :* Preferred regimen (2): [[Tinidazole]] 2 g PO qd for 3 days {{then}} [[Iodoquinol]] 650 mg PO tid for 20 days | ||
| | |||
==References== | |||
{{reflist|2}} | |||
{{WH}} | |||
{{WS}} | |||
[[Category:Gastroenterology]] | |||
[[Category:Mature chapter]] | |||
[[Category:Disease]] | |||
Latest revision as of 18:43, 18 September 2017
Actinomycosis
Treatment
Type | Treatment |
---|---|
Central Nervous system
actinomycosis |
|
Amoebic liver abscess diagnosis
Diagnosis of amoebic liver abscess | |||||||||||||||||||||||||||||||||||||||||||||||
Signs and symptoms(a) Fever, abdominal pain, point tenderness over the liver, hepatomegaly, weight loss History Travel to endemic areas, immigrant from endemic areas, having had dysentery within last years, gender (male/female:9/1 | |||||||||||||||||||||||||||||||||||||||||||||||
Laboratory diagnosis(LD) and Radiologic Methods (RM) (US, CT or MRI) | |||||||||||||||||||||||||||||||||||||||||||||||
LD negative and RM negative:Floow | LD negative and RM positive:aspiration, if possible(b) | LD positive and RM positive: chemotherapy / surgical treatment | |||||||||||||||||||||||||||||||||||||||||||||
Pyogenic abscesses Neoplasia (hepatocellular carcinoma) Cysticercosis Cystic echinococcosis | ALA | ||||||||||||||||||||||||||||||||||||||||||||||
Liver abscess
Liver abscess | |||||||||||||||||||||||||||||||||||||||||||||
Risk factors | |||||||||||||||||||||||||||||||||||||||||||||
Hematogenous | Biliary | Underlying lesions or anamolies | Other causes | ||||||||||||||||||||||||||||||||||||||||||
Portal vein Intra-abdominal infection Pyelophlebitis Abdominal abscess Amoebiasis Arterial ENT Oral cavity | Gall stones Obstructed bile duct Contiguous spread, ascending cholangitis Bile duct ischemia | Biliary cyst Hydatid cyst Cystadenoma Necrosis of a primary tumor Superinfection of a metastasis Caroli disease Biliary stricture Sclerosing cholangitis Ischemic cholangitis | Radiofrequency ablation / Chemoembolization in the presence of infected bile Pancreatoduodenectomy Liver transplantation Hepatic trauma ± arterial embolization | ||||||||||||||||||||||||||||||||||||||||||
Causes liver abscess
Pyogenic liver abscess | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Causes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hepatobiliary | Portal | Arterial | Traumatic | Cryptogenic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Benign | Malignant | Benign | Malignant | • Endocarditis • Vascular sepsis • Dental infection • ENT infection | Benign | Malignant | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Lithiasis • Cholicystitis • Biliary enteric anastomosis • Percutaneous biliary procedures • Endoscopic biliary procedures | • Gall bladder • Common bile duct • Head of pancreas • Ampulla | • Appendicitis • Diverticulitis • Pelvic suppuration • Anorectal suppuration • Pancreatic abscess • Postoperative sepsis • Intestinal perforation • Inflammatory bowel disease | • Gastric cancer • Colon cancer | • Open or closed abdominal trauma | • Percutaneous ethanol injection or radiofrequency • Chemoembolization | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment
Treatment | |||||||||||||||||||||
Non-surgical treatment | Non-surgical treatment | ||||||||||||||||||||
Conservative management with antibiotics alone | Open surgical drainage | ||||||||||||||||||||
Drainage
Drainage | |||||||||||||||||||||||||
Percutaneous drainage | Open surgical drainage | Endoscopic retrograde cholangiopancreatography (ERCP) | |||||||||||||||||||||||
CT guided | CT guided | ||||||||||||||||||||||||
The mainstay of therapy for pyogenic liver abscesses is percutaneous drainage and antimicrobial therapy. Empiric therapy for pyogenic liver abscesses consists of either a second- or third-generation cephalosporin with metronidazole or piperacillin-tazobactam. Amebic liver abscesses are often treated medically with a short course of metronidazole or tinidazole followed by 20 days of iodoquinol.
Medical Therapy
- It is essential to differentiate between pyogenic and amebic liver abscesses for appropriate therapy. Differentiation can be established based on serology, culture results, and response to therapy.[1]
- The mainstay of therapy for pyogenic hepatic abscesses is ultrasound/CT-guided percutaneous drainage with at least 2 weeks (may last up to 6 weeks) of intravenous antibiotics.[2]
- Empiric antibiotics should only be used initially, with diagnostic aspiration and culture performed as soon as possible.
- Amebic liver abscesses can be treated successfully with antimicrobial agents and do not require drainage except in special conditions, such as:[3]
- Severe clinical illness
- Uncertain diagnosis
- No response to metronidazole therapy (after 4 days of treatment)
- Large left-lobe abscesses (risk of rupture into pericardium)
- Imminent rupture
Antibiotic Regimens
- Pyogenic Liver Abscess
-
- Preferred regimen (1): (Ceftriaxone 1-2 g IV/IM q24h OR Cefotaxime 1-2 g IV or IM q8h) AND (Metronidazole 15 mg/kg IV single dose THEN 7.5 mg/kg PO/IV q6h)
- Preferred regimen (2): Ciprofloxacin 400 mg IV q12h AND (Metronidazole 15 mg/kg IV single dose THEN 7.5 mg/kg PO/IV q6h)
- Preferred regimen (3): Piperacillin-Tazobactam 3.375 g IV q6h
- Note: The empiric therapy for pyogenic abscesses should be based on local resistance patterns, with particular attention to resistant Klebsiella spp.. Ampicillin is not recommended due to the high resistance found among Klebsiella spp.. There is no set duration for treatment, which may vary from 2 to 6 weeks.
- 2. Pathogen-directed antimicrobial therapy
- 2.1 Klebsiella spp.[5]
- Preferred regimen: Gentamicin AND (Piperacillin-Tazobactam 3.375 g IV q6h OR Cefazolin 0.5-1 g IV q6-8h OR Ceftriaxone 1-2 g IV/IM q24h OR Cefotaxime 1-2 g IV or IM q8h) for 2–3 wk
- Note: Acute therapy may be followed by 4 weeks of oral antibiotics (fluoroquinolone or second/third-generation cephalosporin).
- Amebic Liver Abscess
- Preferred regimen (1): Metronidazole 2-4 g PO qd for 2 days THEN Iodoquinol 650 mg PO tid for 20 days
- Preferred regimen (2): Tinidazole 2 g PO qd for 3 days THEN Iodoquinol 650 mg PO tid for 20 days
References
- ↑ Lodhi S, Sarwari AR, Muzammil M, Salam A, Smego RA (2004). "Features distinguishing amoebic from pyogenic liver abscess: a review of 577 adult cases". Trop Med Int Health. 9 (6): 718–23. doi:10.1111/j.1365-3156.2004.01246.x. PMID 15189463.
- ↑ 2.0 2.1 Heneghan HM, Healy NA, Martin ST, Ryan RS, Nolan N, Traynor O; et al. (2011). "Modern management of pyogenic hepatic abscess: a case series and review of the literature". BMC Res Notes. 4: 80. doi:10.1186/1756-0500-4-80. PMC 3073909. PMID 21435221.
- ↑ Stanley SL (2003). "Amoebiasis". Lancet. 361 (9362): 1025–34. doi:10.1016/S0140-6736(03)12830-9. PMID 12660071.
- ↑ Rahimian J, Wilson T, Oram V, Holzman RS (2004). "Pyogenic liver abscess: recent trends in etiology and mortality". Clin Infect Dis. 39 (11): 1654–9. doi:10.1086/425616. PMID 15578367.
- ↑ 5.0 5.1 Lederman ER, Crum NF (2005). "Pyogenic liver abscess with a focus on Klebsiella pneumoniae as a primary pathogen: an emerging disease with unique clinical characteristics". Am J Gastroenterol. 100 (2): 322–31. doi:10.1111/j.1572-0241.2005.40310.x. PMID 15667489.
- ↑ Lübbert C, Wiegand J, Karlas T (2014). "Therapy of Liver Abscesses". Viszeralmedizin. 30 (5): 334–41. doi:10.1159/000366579. PMC 4513824. PMID 26287275.
- ↑ Kurland JE, Brann OS (2004). "Pyogenic and amebic liver abscesses". Curr Gastroenterol Rep. 6 (4): 273–9. PMID 15245694.